Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HL192
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Hanall Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
HanAll, Daewoong and NurrOn Complete First Human Parkinson’s Therapy Study
Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : HL192
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Hanall Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATH-399A
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Hanall Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : ATH-399A
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Hanall Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATH-399A
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Hanall Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 25, 2023
Lead Product(s) : ATH-399A
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Hanall Biopharma
Deal Size : Undisclosed
Deal Type : Agreement